Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Zampilimab

Generic Name: Zampilimab

Drug Type: Biotech

CAS Number: 2098280-42-1

Unique Ingredient Identifier: 52B38H09GZ

Overview

Zampilimab is under investigation in clinical trial NCT04335578 (A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of UCB7858 in Adult Kidney Transplant Recipients With Chronic Allograft Injury).

Background

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

A Study to Test Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Intravenous Doses of Zampilimab in Healthy Participants

Phase 1

Completed

Posted: 2021/01/12

Sponsor:UCB Biopharma SRL

ID:NCT04705350

A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Zampilimab in Adult Kidney Transplant Recipients With Chronic Allograft Injury

Phase 1

Terminated

Posted: 2020/04/06

Sponsor:UCB Biopharma SRL

ID:NCT04335578

A First-In-Human Study With a Single Ascending Dose of UCB7858 in Healthy Volunteers

Phase 1

Completed

Posted: 2016/08/26

Sponsor:

UCB Biopharma S.P.R....

ID:NCT02879877

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

No news found

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy